Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Santen Pharmaceutical Co (SNPHY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.39 -0.17    -1.78%
26/04 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 288
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 9.39 - 9.39
Santen Pharmaceutical Co 9.39 -0.17 -1.78%

SNPHY Balance Sheet

 
Featured here, the Balance Sheet for Santen Pharmaceutical Co, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 224606 215975 203266 213326
Cash and Short Term Investments 83358 66359 47094 58677
Cash - - - -
Cash & Equivalents 82030 64728 45510 57903
Short Term Investments 1328 1631 1584 774
Total Receivables, Net 84940 93486 103831 107225
Accounts Receivables - Trade, Net 84935 93486 103773 107165
Total Inventory 46923 45569 42228 39352
Prepaid Expenses - - - -
Other Current Assets, Total 9385 10561 10113 8072
Total Assets 427820 426984 416528 421179
Property/Plant/Equipment, Total - Net 68451 69487 68425 66173
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - - 7385
Intangibles, Net 91460 94832 97083 88924
Long Term Investments 39947 43074 44807 42560
Note Receivable - Long Term 5 - 58 60
Other Long Term Assets, Total - 1 35357 1
Other Assets, Total -23948 -32110 -46959 -56217
Total Current Liabilities 91438 81083 76192 89504
Accounts Payable 45121 43878 41330 44945
Payable/Accrued - - - -
Accrued Expenses - - - -
Notes Payable/Short Term Debt - - - 245
Current Port. of LT Debt/Capital Leases - - - 2811
Other Current liabilities, Total 46317 37205 34862 41503
Total Liabilities 129836 120529 116309 127883
Total Long Term Debt - - - 33151
Long Term Debt - - - 28198
Capital Lease Obligations - - - 4953
Deferred Income Tax 1185 1860 1929 1592
Minority Interest -736 -735 -706 -683
Other Liabilities, Total 37949 38321 38894 -4369
Total Equity 297984 306455 300219 293296
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 8769 8756 8707 8702
Additional Paid-In Capital 9509 9373 9955 9789
Retained Earnings (Accumulated Deficit) 253167 251706 242661 238071
Treasury Stock - Common -16398 -11324 -7372 -364
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 42937 47944 46268 37098
Total Liabilities & Shareholders' Equity 427820 426984 416528 421179
Total Common Shares Outstanding 363.19 367.77 369.9 375.54
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SNPHY Comments

Write your thoughts about Santen Pharmaceutical Co
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email